Adult T-cell lymphoma/leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adult T-cell lymphoma/leukaemia recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Selinexor, Ifosfamide, Etoposide, and Dexamethasone for Patients with Relapsed or Refractory Peripheral T-cell Lymphomas https://clinicaltrials.eu/trial/study-of-selinexor-ifosfamide-etoposide-and-dexamethasone-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ Wed, 29 Apr 2026 14:29:19 +0000 https://clinicaltrials.eu/trial/study-of-selinexor-ifosfamide-etoposide-and-dexamethasone-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ This clinical trial is focused on studying a type of cancer known as Peripheral T-cell Lymphoma, which has either returned after treatment or has not responded to previous treatments. The study is testing a combination of medications to see how well they work together. The medications being used in this study are Selinexor (also known by its code name KPT-330), Ifosfamide, Etoposide, and Dexamethasone. These medications are being tested together to see if they can help improve the condition of patients with this type of lymphoma.

The purpose of the study is to determine how effective this combination of medications is in treating the lymphoma. Participants in the study will receive these medications over a series of treatment courses. The study will monitor the response of the lymphoma to the treatment, looking for signs of improvement such as a reduction in the size of the cancer or a complete disappearance of the cancer. The study will also keep track of any side effects that participants may experience while taking these medications.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the progress of the treatment. The study aims to provide valuable information on whether this combination of medications can be a successful treatment option for patients with relapsed or refractory Peripheral T-cell Lymphoma. The results of this study could help improve future treatment options for this challenging condition.

]]>